Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...
- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of Citius' novel...
Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).
Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR)
Summary
IDMC meets on June 29 for Superiority review.Mino-Lok has no competition.Price target increased to...
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21
Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
We're up 370% since adding it to the Biotech Stock Review Watch List...
Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
https://youtu.be/vMIy8xWLOKI?t=3699
INSIDER HOLDINGS
POWERPOINT
LIVE CHART
Adding Citius (CTXR) $0.55 to Watch List.
Citius News Archive
MARKET BEAT
TIP RANKS
Disclaimer. Citius Pharma is a client, please see reports for disclosure and...
Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.
The 2021 Biotech Six Pack: Stocks We Expect to Double!
These are ideas #3 and #4 for the 'Biotech Six Pack' list. The first addition...
Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.
The 2021 Biotech Six Pack, Six Stocks We Expect to Double.
We're still putting the 2021 list together now, but rather than waiting to announce...
Short Squeeze Mania.
Citius Pharma (CTXR) Locked and Loaded.
Truly Locked and Loaded. Latest $20 Million Round is Biggest News We've Seen From Citius Pharma (CTXR) Since We've...
Make Hay While the Sun Shines. Up 6,400%.
Celcius (CELH) We're Up 6,400%. Alkaline Water (WTER) We're Up 12%.Dicerna (DRNA) We're Up 700%. Ready to Breakout?BioSig (BSGM) We Have Another Double. BioSig...
Newsletter: Institutional Analyst. And Yes, We Have Another Double.
1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3. BioSig (BSGM) $4.70. We're Up 60%,...
Committed to Win. C-1 and Dyadic’s (DYAI) Drive to Make Vaccines Affordable Worldwide.
Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression...
Latest article
Cabaletta (CABA) Surges 44% on Massive Volume Spike.
Biotech 12 Pack Off to Nice Start..
Cabaletta up 35%, GeoVax up 75%, and Replimune up 62%. All since late April!
Biotech Stock Review is...
GeoVax (GOVX) Surges 51% on Massive Volume Spike.
MonkeyPox and Gedeptin Related News Spark New Investor Interest.
MARKET BRIEF
On a quiet Wednesday afternoon, the 29th, while we were nearing completion of an updated...
Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
